Scolaris Content Display Scolaris Content Display

Neuromuskuläre elektrische Stimulation (NMES) zur Behandlung des femoropatellaren Schmerzsyndroms

Contraer todo Desplegar todo

Referencias

References to studies included in this review

Akarcali 2002 {published data only}

Akarcali I. Additional information on random sequence generation, allocation concealment and blinding [personal communication] Email to: AL Martimbianco 10 March 2015. CENTRAL
Akarcali I, Tugay N, Kaya D, Atay A, Doral MN. The role of high voltage electrical stimulation in the rehabilitation of patellofemoral pain. The Pain Clinic 2002;14(3):207–12. CENTRAL

Bily 2008 {published data only}

Bily W. Additional information on random sequence generation, allocation concealment and blinding (participants, personnel and assessors) [personal communication]. Email to: AL Martimbianco 16 March 2015. CENTRAL
Bily W. Additional information regarding which knee was treated and assessed [personal communication]. Email to: AL Martimbianco 9 August 2016. CENTRAL
Bily W, Trimmel L, Mödlin M, Kaider A, Kern H. Training program and additional electric muscle stimulation for patellofemoral pain syndrome: a pilot study. Archives of Physical Medicine and Rehabilitation 2008;89:1230‐6. CENTRAL

Callaghan 2001 {published data only}

Callaghan MJ. Additional information on NMES parameters [personal communication]. Email to: AL Martimbianco 9 March 2015. CENTRAL
Callaghan MJ, Oldham JA, Winstanley J. A comparison of two types of electrical stimulation of the quadriceps in the treatment of patellofemoral pain syndrome. A pilot study. Clinical Rehabilitation 2001;15:637–46. CENTRAL

Callaghan 2004 {published data only}

Callaghan M. Additional information on NMES parameters [personal communication]. Email to: AL Martimbianco 9 March 2015. CENTRAL
Callaghan MJ, Oldham JA. Electric muscle stimulation of the quadriceps in the treatment of patellofemoral pain. Archives of Physical Medicine and Rehabilitation 2004;85:956‐62. CENTRAL

Glaviano 2016 {published data only}

Glaviano N. Additional information on random sequence generation, allocation concealment and blinding (participants, personnel and assessors) [personal communication]. Email to: AL Martimbianco 12 August 2016. CENTRAL
Glaviano NR, Huntsman S, Dembeck A, Hart JM, Saliba S. Improvements in kinematics, muscle activity and pain during functional tasks in females with patellofemoral pain following a single patterned electrical stimulation treatment. Clinical Biomechanics 2016;32:20‐7. CENTRAL
Glaviano NR, Saliba SA. Immediate effect of patterned neuromuscular electrical stimulation on pain and muscle activation in individuals with patellofemoral pain. Journal of Athletic Training 2016;51(2):118‐28. CENTRAL

Gobelet 1992 {published data only}

Gobelet C, Frey M, Bonard A. Muscle training techniques and retropatellar chondropathy [Techniques de musculation et chondropathie rétro‐patellaire]. Revue du Rhumatismeet des Maladies Osteo‐Articulaires 1992;59(1):23‐7. CENTRAL

Kaya 2013 {published data only}

Kaya D, Yüksel Ý, Callaghan MJ, Güney H, Atay ÖA, Çitaker S, et al. High voltage pulsed galvanic stimulation adjunct to rehabilitation program for patellofemoral pain syndrome: a prospective randomized controlled trial. Fizyoterapi Rehabilitasyon 2013;24(1):1‐8. CENTRAL

Tunay 2003 {published data only}

Tunay VB. Additional information on NMES parameters and exercise programme [personal communication]. Email to: AL Martimbianco 12 March 2015. CENTRAL
Tunay VB, Baltaci G, Tunay S, Ergun N. A comparison of different treatment approaches to patellofemoral pain syndrome. The Pain Clinic 2003;15(2):179‐84. CENTRAL

References to studies excluded from this review

Dursun 2001 {published data only}

Dursun N, Dursun E, Kiliç Z. Electromyographic biofeedback–controlled exercise versus conservative care for patellofemoral pain syndrome. Archives of Physical Medicine and Rehabilitation 2001;82:1692‐5. CENTRAL

Kuru 2012 {published data only}

Kuru T, Yaliman A, Dereli EE. Comparison of efficiency of Kinesio taping and electrical stimulation in patients with patellofemoral pain syndrome. Acta Orthopaedica et Traumatologica Turcica 2012;46(5):385‐92. CENTRAL

NCT02441712 {published data only}

NCT02441712. Rehabilitation with patterned electrical neuromuscular stimulation for patients with patellofemoral pain (PENS for PFP). clinicaltrials.gov/ct2/show/NCT02441712 (first received 12 May 2015). CENTRAL

Barton 2009

Barton CJ, Levinger P, Menz HB, Webster KE. Kinematic gait characteristics associated with patellofemoral pain syndrome: a systematic review. Gait & Posture 2009;30(4):405‐16.

Bolgla 2011

Bolgla LA, Boling MC. An update for the conservative management of patellofemoral pain syndrome: a systematic review of the literature from 2000 to 2010. International Journal of Sports Physical Therapy 2011;6(2):112‐25.

Chiu 2012

Chiu JK, Wong YM, Yung PS, Ng GY. The effects of quadriceps strengthening on pain, function, and patellofemoral joint contact area in persons with patellofemoral pain. American Journal of Physical Medicine & Rehabilitation 2012;91(2):98‐106.

Collins 2013

Collins NJ, Bierma‐Zeinstra SM, Crossley KM, van Linschoten RL, Vicenzino B, van Middelkoop M. Prognostic factors for patellofemoral pain: a multicentre observational analysis. British Journal of Sports Medicine 2013;47(4):227‐33.

CONSORT 2010

Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology 2010;63(8):834–40.

Cowan 2009

Cowan SM, Crossley KM, Bennell KL. Altered hip and trunk muscle function in individuals with patellofemoral pain. British Journal of Sports Medicine 2009;43(8):584‐8.

Crossley 2002

Crossley K, Bennell K, Green S, Cowan S, McConnell J. Physical therapy for patellofemoral pain: a randomized, double‐blinded, placebo‐controlled trial. American Journal of Sports Medicine 2002;30(6):857‐65.

Crossley 2004

Crossley KM, Bennell KL, Cowan SM, Green S. Analysis of outcome measures for persons with patellofemoral pain: which are reliable and valid?. Archives of Physical Medicine and Rehabilitation 2004;85(5):815‐22.

Davies 2000

Davies AP, Costa ML, Shepstone L, Glasgow MM, Donell S. The sulcus angle and malalignment of the extensor mechanism of the knee. Journal of Bone and Joint Surgery ‐ British Volume 2000;82(B):1162‐6.

Doucet 2012

Doucet BM, Lam A, Griffin L. Neuromuscular electrical stimulation for skeletal muscle function. Yale Journal of Biology and Medicine 2012;85(2):201‐15.

Dye 2005

Dye SF. The pathophysiology of patellofemoral pain: a tissue homeostasis perspective. Clinical Orthopaedics and Related Research 2005;436:100‐10.

Fagan 2008

Fagan V, Delahunt E. Patellofemoral pain syndrome: a review on the associated neuromuscular deficits and current treatment options. British Journal of Sports Medicine 2008;42(10):489‐95.

Frye 2012

Frye JL, Ramey LN, Hart JM. The effects of exercise on decreasing pain and increasing function in patients with patellofemoral pain syndrome: a systematic review. Sports Health 2012;4(3):205‐10.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Kaya 2011

Kaya D, Citaker S, Kerimoglu U, Atay OA, Nyland J, Callaghan M, et al. Women with patellofemoral pain syndrome have quadriceps femoris volume and strength deficiency. Knee Surgery, Sports Traumatology, Arthroscopy 2011;19(2):242‐7.

Kendall 2005

Kendall FP, McCreary EK, Provance PG, Rodgers MM, Romani WA. Muscles: Testing and Function, With Posture and Pain. 5th Edition. Baltimore: Lippincott Williams & Wilkins, 2005.

Kujala 1993

Kujala UM, Jaakkola LH, Koskinen SK, Taimela S, Hurme M, Nelimarkka O. Scoring of patellofemoral disorders. Arthroscopy 1993;9(2):159‐63.

Lake 2011

Lake DA, Wofford NH. Effect of therapeutic modalities on patients with patellofemoral pain syndrome: a systematic review. Sports Health 2011;3(2):182‐9.

Lankhorst 2012

Lankhorst NE, Bierma‐Zeinstra SM, van Middelkoop M. Risk factors for patellofemoral pain syndrome: a systematic review. Journal of Orthopaedic and Sports Physical Therapy 2012;42(2):81‐94.

Lefebvre 2011

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Lysholm 1982

Lysholm J, Gillquist J. Evaluation of the knee ligament surgery results with special emphasis on use of a scoring scale. American Journal of Sports Medicine 1982;10(3):150‐4.

Maddocks 2013

Maddocks M, Gao W, Higginson IJ, Wilcock A. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD009419.pub2]

Maffiuletti 2010

Maffiuletti NA. Physiological and methodological considerations for the use of neuromuscular electrical stimulation. European Journal of Applied Physiology 2010;110(2):223‐34.

Maffiuletti 2014

Maffiuletti NA, Vivodtzev I, Minetto MA, Place N. A new paradigm of neuromuscular electrical stimulation for the quadriceps femoris muscle. European Journal of Applied Physiology 2014;114(6):1197‐205. [DOI: 10.1007/s00421‐014‐2849‐2]

Monaghan 2010

Monaghan B, Caulfield B, O’Mathúna DP. Surface neuromuscular electrical stimulation for quadriceps strengthening pre and post total knee replacement. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007177.pub2]

Pal 2012

Pal S, Besier TF, Draper CE, Fredericson M, Gold GE, Beaupre GS, et al. Patellar tilt correlates with vastus lateralis: vastus medialis activation ratio in maltracking patellofemoral pain patients. Journal of Orthopaedic Research 2012;30(6):927‐33.

Pattyn 2012

Pattyn E, Mahieu N, Selfe J, Verdonk P, Steyaert A, Witvrouw E. What predicts functional outcome after treatment for patellofemoral pain?. Medicine and Science in Sports Exercise 2012;44(10):1827‐33.

Petersen 2013

Petersen W, Ellermann A, Gösele‐Koppenburg A, Best R, Rembitzki IV, Brüggemann GP, et al. Patellofemoral pain syndrome. Knee Surgery, Sports Traumatology, Arthroscopy 2013 Nov 13 [Epub ahead of print]. [DOI: 10.1007/s00167‐013‐2759‐6]

Powers 2003

Powers CM. The influence of altered lower‐extremity kinematics on patellofemoral joint dysfunction: a theoretical perspective. Journal of Orthopaedic and Sports Physical Therapy 2003;33(11):639‐46.

Powers 2012

Powers CM, Bolgla LA, Callaghan MJ, Collins N, Sheehan FT. Patellofemoral pain: proximal, distal, and local factors, 2nd International Research Retreat. Journal of Orthopaedic and Sports Physical Therapy 2012;42(6):A1‐54.

Rathleff 2012

Rathleff MS, Roos EM, Olesen JL, Rasmussen S. Early intervention for adolescents with patellofemoral pain syndrome ‐ a pragmatic cluster randomised controlled trial. BMC Musculoskeletal Disorders 2012;27(13):1‐9. [DOI: 10.1186/1471‐2474‐13‐9]

Rathleff 2013

Rathleff MS, Roos EM, Olesen JL, Rasmussen S, Arendt‐Nielsen L. Lower mechanical pressure pain thresholds in female adolescents with patellofemoral pain syndrome. Journal of Orthopaedic and Sports Physical Therapy 2013;43(6):414‐21.

Revill 1976

Revill SI, Robinson JO, Rosen M, Hogg MI. The reliability of a linear analogue for evaluating pain. Anaesthesia 1976;31(9):1191‐8.

RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Roush 2012

Roush JR, Curtis Bay R. Prevalence of anterior knee pain in 18‐35 year‐old females. International Journal of Sports Physical Therapy 2012;7(4):396‐401.

Salsich 2001

Salsich GB, Brechter JH, Powers CM. Lower extremity kinetics during stair ambulation. Clinical Biomechanics 2001;16:906‐12.

Sillen 2013

Sillen MJ, Franssen FM, Gosker HR, Wouters EF, Spruit MA. Metabolic and structural changes in lower‐limb skeletal muscle following neuromuscular electrical stimulation: a systematic review. PLoS ONE 2013;8(9):e69391.

Smith 2015

Smith TO, Drew BT, Meek TH, Clark AB. Knee orthoses for treating patellofemoral pain syndrome. Cochrane Database of Systematic Reviews 2015, Issue 12. [DOI: 10.1002/14651858.CD010513.pub2]

Taradaj 2013

Taradaj J, Halski T, Kucharzewski M, Walewicz K, Smykla A, Ozon M, et al. The effect of neuromuscular electrical stimulation on quadriceps strength and knee function in professional soccer players: return to sport after ACL reconstruction. Biomed Research International 2013 Dec 5 [Epub ahead of print]. [DOI: 10.1155/2013/802534]

van der Heijden 2015

van der Heijden RA, Lankhorst NE, van Linschoten R, Bierma‐Zeinstra SMA, van Middelkoop M. Exercise for treating patellofemoral pain syndrome. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD010387.pub2]

Vanderthommen 2007

Vanderthommen M, Duchateau J. Electrical stimulation as a modality to improve performance of the neuromuscular system. Exercise and Sport Sciences Review 2007;35(4):180‐5.

Vengust 2001

Vengust R, Strojnik V, Pavlovcic V, Antolic V, Zupanc O. The effect of electrostimulation and high load exercises in patients with patellofemoral joint dysfunction. A preliminary report. European Journal of Physiology 2001;442(6):153‐4.

Ware 1992

Ware JE, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36) I. Conceptual framework and item selection. Medical Care 1992;30(6):473‐83.

Werner 1993

Werner S, Arvidsson H, Arvidsson I, Eriksson E. Electrical stimulation of vastus medialis and stretching of lateral thigh muscles in patients with patello‐femoral symptoms. Knee Surgery, Sports Traumatology, Arthroscopy 1993;1(2):85‐92.

Witvrouw 2014

Witvrouw E, Callaghan MJ, Stefanik JJ, Noehren B, Bazett‐Jones DM, Willson JD, et al. Patellofemoral pain: consensus statement from the 3rd International Patellofemoral Pain Research Retreat held in Vancouver, September 2013. British Journal of Sports Medicine 2014;48(6):411‐4.

References to other published versions of this review

Martimbianco 2014

Martimbianco ALC, Torloni MR, Andriolo BNG, Porfirio G, Riera R. Neuromuscular electrical stimulation (NMES) for patellofemoral pain syndrome. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011289]

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Akarcali 2002

Methods

Randomised controlled trial

Trial protocol registration: not reported

Participants

Country: Turkey

Setting: Hacettepe University, School of Physiotherapy and Rehabilitation, and Department of Orthopaedics and Traumatology, Ankara

Data collection period: not reported

Inclusion criteria: anterior knee pain (longer than 2 months), positive patellar compression test, age between 15 and 45 years, negative findings in the clinical examination of knee ligaments, bursae, menisci, synovial plicae, hamstring, quadriceps, and patellar tendons

Exclusion criteria: history or clinical evidence of patellofemoral dislocation, subluxation, or severe osteoarthritis, X‐rays showing lateral displacement of the patella

Mean duration of symptoms: 15.74 ± 9.31 months

62.5% of bilateral complaints, but only the most symptomatic knee was treated

Study participants: 44 people with patellofemoral pain assigned and 42 assessed

  1. NMES + exercise: n = 22/available for analysis = 20

  2. Only exercises: n = 22/available for analysis = 22

Mean age (SD): 39.0 (9.6) years

Gender (number of women/men): 31/13

Interventions

Comparison: NMES + other intervention (exercise) versus no NMES + same other intervention

Treatment duration: 6 weeks
Treatment setting: outpatient rehabilitation programme

Details of interventions:

  1. NMES programme: Portable HVPGS, monophasic (twin‐peak pulse) waveform, pulse duration 65 to 75 µs, intensity amplitude ranges from 0 to 300 V, pulse frequency of 60 pulses per second. 2 self adhesive electrodes positioned over the VMO: the proximal electrode was placed 4 cm superior to the superomedial border of the patella, and the distal electrode 3 cm medial to this point. Participants in weight‐bearing position with a comfortable amount of knee flexion. The muscle was stimulated while the participant executed an active contraction of the quadriceps. The intensity of stimulation was adjusted to a level that induced a contraction as close as to a maximum voluntary contraction but without patellofemoral pain. Treatment duration: 10 minutes, 5 times a week.

  2. Exercise programme: Both groups followed the same exercise programme (total of 30 sessions). First 2 weeks: quadriceps sets, straight leg raises, hip adductor strengthening exercises (to facilitate VMO contraction), eccentric quadriceps contraction by leg‐lowering exercises, leg pulls using a rubber tube. Weeks 2 to 4: bilateral shallow squats, toe rises on both feet, leg pulls using a rubber tube in a standing position, stretching exercises for iliotibial band, hamstring, quadriceps, and triceps surae muscles. Weeks 4 to 6: step‐downs, bilateral deep squats, 1‐legged shallow squats, exercises for lower extremity balance, cycling on a stationary bicycle, toe raises of 1 foot, hopping activities. The progression of load and exercises was individually prescribed according to the level of perceived pain. Ice was used after exercises to minimise latent soft‐tissue pain.

Outcomes

Outcomes analysed in the study and used in this review:

  1. Knee pain: VAS

  2. Muscle strength: assessed through Lovett’s manual muscle test (graded between 0 and 5; higher scores indicating better muscle strength) (Kendall 2005):

    • zero indicates no contraction;

    • 1 indicates visible muscle contraction without joint movement;

    • 2‐ to 2+ indicates poor strength (ability to move through full active range of motion);

    • 3‐ to 3+ indicates fair strength (hold test position);

    • 4‐ to 4+ indicates good strength (hold test position against slight to moderate manual resistance);

    • 5 indicates normal strength (hold test position against strong manual resistance).

Follow‐up assessments: at 6 weeks (at end of treatment)

Notes

Description of condition: patellofemoral pain syndrome

The trial authors provided additional information on random sequence generation, allocation concealment, and blinding (participants, personnel, and assessors) via email (10 March 2015).

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Quote: "The subjects were randomly introduced into either HVPGS and exercise, or only exercise (control group)"

Authors' reply: "At the time of study, it was feasible for us to use coin tossing technique to assign patients to either HVPGS and exercise group, or only exercise (control group) in consecutively."

Allocation concealment (selection bias)

Unclear risk

Available information did not permit judgement.

Authors' reply: "Assigning patients to intervention groups was done by the first author with coin tossing technique to prevent second and third author/researcher from influencing concealing the allocation sequence in the study."

Blinding of participants and personnel (performance bias)
All outcomes

High risk

Available information did not permit judgement.

Authors' reply: "Patients were also blinded to their intervention groups. Exercise programs were applied by physiotherapist (third researcher/author)"

However, since no sham/placebo was used, it is unlikely that the blinding was kept.

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

Available information did not permit judgement.

Authors reply: "Pre and post treatment muscle strength and VAS measurements were evaluated by the same physiotherapist (second researcher) who is blind from the patient’s group"

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Quote: “Two patients of the HVPGS group did not complete the study and their data results were excluded” (4.5% dropout)

No reasons were provided. We are uncertain of the potential effect of these missing data.

Selective reporting (reporting bias)

Unclear risk

No study protocol available. It is not clear if the results included all expected outcomes (e.g. retropatellar pain during activities: steps up and down and squatting). This study did not consider adverse event as an outcome.

Other bias

Low risk

The study appears to be free of other sources of bias. Baseline characteristics were balanced between groups.

Bily 2008

Methods

Randomised controlled trial

Trial protocol registration: not reported

Participants

Country: Austria

Setting: Department of Physical Medicine and Rehabilitation, Wilhelminenspital Vienna and Core Unit for Medical Statistics and Informatics, Section of Clinical Biometrics, Medical University of Vienna

Data collection period: between June 2003 and August 2005

Inclusion criteria: bilateral anterior knee pain for 6 to 120 months and at least 3 of the following 4 clinical criteria: pain associated with prolonged sitting with bended knees, descending stairs, kneeling and squatting, or sports activities

Exclusion criteria: clinical evidence of patellar dislocation or subluxation, periarticular bursitis or tendonitis, ligamentous instability, or intra‐articular pathology. Before beginning therapy, all participants were thoroughly clinically examined. Those who did not reveal any obvious reason for a systemic disorder like patellar or lower‐extremity alignment problems or benign joint hypermobility syndrome were not excluded. To rule out osteoarthritic changes or hypoplastic femoral trochlea, radiographs were performed. Pregnancy, a history of knee surgery, or oral or intra‐articular administration of drugs within the last 3 months

Mean duration of symptoms: 14 months (6 to 24)

Only bilateral complaints (but did not clarify which knee was treated and assessed)

Study participants: 38 people with patellofemoral pain assigned and 29 assessed

  1. NMES + exercise: n = 19/available for analysis after treatment = 18; and after 12 months = 13

  2. Only exercises: n = 19/available for analysis after treatment = 18; and after 12 months = 16

Mean age (SD): 25.4 (6.7) years

Gender (number of women/men): 24/14

Interventions

Comparison: NMES + other intervention (exercise) versus no NMES + same other intervention

Treatment duration: 12 weeks
Treatment setting: at home

Details of interventions:

  1. NMES programme: 2‐channel portable device, asymmetric biphasic pulses for a duration of 0.26 ms, duty cycle of 5:10, maximal amplitude 80 mA, frequency 40 Hz. Four self adhesive electrodes were placed respectively on both ends of the quadriceps muscles. Treatment duration: 2 20‐minute sessions with a minimum of 60‐minute rests between each session. The intensity of the stimulation was kept as high as possible; however, pain tolerance and participant discomfort were modifying factors.

  2. Training programme: Both groups of participants followed the same exercise programme: isometric, concentric, excentric leg raises, stepping and squatting exercises. Balance exercises started from week 4 onward and consisted of standing on 1 leg for 2 minutes each. To increase the exercise demand, participants were instructed to draw circles in the air with the free contralateral leg from week 6 onward. From week 8 onward, participants had to do the 1‐legged balance exercises in a toe‐raised position with drawing circles with the contralateral leg in weeks 11 and 12. Static stretching exercises of the calf and thigh muscles consisted of 3 sets of 10‐second passive sustained stretching for each muscle group performed by the participants themselves at the end of each training session from weeks 4 to 12. Treatment duration: participants were instructed on daily training during the first 2 weeks and had a group session once a week under the supervision of the same physical therapist. From the third week on, they were instructed to train with higher loads 3 times a week for a total of 12 weeks.

Outcomes

Outcomes analysed in the study and used in this review:

  1. Knee pain: VAS, during activities (descending stairs, prolonged sitting, kneeling, or squatting) and during sport movements (walking, jogging, jumping)

  2. Knee function: Kujala Patellofemoral Score

  3. Muscle strength: Strength measurements were performed in a sitting position using a specifically designed chair. Strain gauges, connected in a full bridge circuit configuration, were placed on a lever near the centre of rotation and the output fed to a measurement amplifier. Participants were fixed with shoulder and hip straps and performed 3 maximal isometric contractions of the knee extensors of 10 seconds in 30° and 60° knee flexion with a 2‐minute rest between the contractions. The peak extension torque was recorded, and the best result of the 3 attempts was used for calculation.

Follow‐up assessments: at 12 weeks (at end of treatment) and 1 year

Notes

Description of condition: patellofemoral pain syndrome

The trial authors provided additional information on random sequence generation, allocation concealment and blinding (participants, personnel, and assessors) via email (16 March 2015).

Additionally, the trial authors provided information regarding which knee was treated and assessed (9 August 2016). Authors' reply: "EMS was applied on both knees"

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Authors' reply: "Random allocation of the patients to the 2 treatment groups was performed by using shuffled sealed envelopes”

Allocation concealment (selection bias)

Unclear risk

Authors' reply: "With sealed envelopes"

The authors did not mention if the envelopes were opaque.

Blinding of participants and personnel (performance bias)
All outcomes

High risk

Participants: probably not done because the interventions were different between groups.
Personnel: probably not done due to the nature of the intervention.

Authors' reply: No measures were used to ensure blinding.

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Available information did not permit judgement.

Authors' reply: No measures were used to ensure blinding.

Incomplete outcome data (attrition bias)
All outcomes

High risk

Some participants did not complete the study (5.2% dropout at the end of the treatment and 19% dropout in the long term), and it is unclear how the authors dealt with these missing data.

Selective reporting (reporting bias)

Unclear risk

No study protocol available. It is not clear if the results included all expected outcomes. This study did not consider adverse event as an outcome.

Other bias

Unclear risk

The study appears to be free of other sources of bias. However, although baseline characteristics were balanced between groups, muscle strength before training was greater in the NMES group.

Callaghan 2001

Methods

Randomised controlled trial

Trial protocol registration: not reported

Participants

Country: United Kingdom

Setting: Centre for Rehabilitation Science, Manchester Royal Infirmary, Manchester

Data collection period: not reported

Inclusion criteria: atraumatic peripatellar pain (greater than 6 months and not longer than 3 years); patellofemoral pain was provoked by 1 of the following alone or in combination: prolonged sitting, deep squatting, kneeling, ascending or descending stairs; quadriceps cross‐sectional area differences between affected and unaffected limb greater than 4%

Exclusion criteria: epilepsy, cancer, cardiac pacemaker, suspected heart problem, recent surgery (not including arthroscopy). In order to exclude abnormal foot and ankle pronation as the cause of patellofemoral pain, the participants were screened by kinetic gait analysis to detect abnormal values of mediolateral force. Pain from the lumbar spine and hip joint, severe leg length discrepancy, knee ligament, quadriceps tendon, and meniscal pathologies, Hoffa’s syndrome, medial plica syndrome, femoral anteversion and tibial torsion

Mean duration of symptoms: not reported

All unilateral complaints

Study participants: 16 people with patellofemoral pain assigned and 14 assessed

  1. NMES (simultaneously delivered frequencies): n = 8/available for analysis = 7

  2. NMES (sequentially delivered frequencies): n = 8/available for analysis = 7

Mean age (SD): 29.6 (5.9) years

Gender (number of women/men): 12/2

Interventions

Comparison: NMES (simultaneous mixed frequencies) versus control NMES (sequential mixed frequencies)

Treatment duration: 6 weeks
Treatment setting: at home

Details of interventions:

  1. NMES with simultaneously combined high‐ and low‐frequency components: 2‐channel portable, asymmetrical biphasic pulse, maximum amplitude of 90 mA, duty cycle of 10:50, pulse duration 200 μs. Stimulation pattern: 3 simultaneously delivered components (a background low‐frequency component, a high‐frequency component superimposed on the background at regular intervals, and a ‘doublet’ of pulses delivered within the higher‐frequency burst). 2 self adhesive electrodes positioned over the quadriceps muscle group. Treatment duration: 60 minutes daily, for 6 weeks.

  2. NMES with sequentially combined frequencies: 3‐channel stimulator, bipolar, biphasic asymmetrical rectangular pulses. Stimulation parameters and treatment duration: once a day, 5 days a week for the first 2 weeks (2 minutes at 8 Hz pulse width 250 μs; 20 minutes at 35 Hz pulse width 350 μs; 3 minutes at 3 Hz pulse width 250 μs), and then 3 times a week for weeks 3 and 4 and twice a week for the last 2 weeks (2 minutes at 8 Hz pulse width 250 μs; 20 minutes at 45 Hz pulse width 350 μs; 3 minutes at 3 Hz pulse width 250 μs). 2 self adhesive electrodes positioned over the quadriceps muscle group.

Outcomes

Outcomes analysed in the study and used in this review:

  1. Knee pain: VAS

  2. Knee function: Kujala Patellofemoral Score

  3. Adverse events: muscle fatigue rate assessed by bipolar electrode surface EMG (median frequency calculated at 1‐second intervals during a sustained 60‐second contraction at 60% of maximum)

  4. Lower limb muscle function: functional performance tests: step‐up (the number of steps the participant could climb up onto a 25‐centimetre step), step‐down (the number of steps down a 25‐centimetre step), and squat flexion (the amount of knee flexion participants could achieve from a standing position until the onset of their patellar pain, measured by a universal goniometer)

  5. Muscle strength: quadriceps isometric and isokinetic muscle strength measured through an isokinetic dynamometer (angular velocity at 90°/s)

Follow‐up assessments: 6 weeks (at end of treatment)

Notes

Description of condition: patellofemoral pain syndrome

The trial authors provided additional information on NMES parameters via email (9 March 2015).

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Quote: "Patients were randomly allocated by computer program to either the experimental stimulation or standard stimulation treatment regimes"

Allocation concealment (selection bias)

Unclear risk

Available information did not permit judgement.

Blinding of participants and personnel (performance bias)
All outcomes

Unclear risk

Participants: Available information did not permit judgement.
Personnel: Available information did not permit judgement.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Available information did not permit judgement.

Incomplete outcome data (attrition bias)
All outcomes

High risk

2 participants (12% dropout) did not complete the study and were excluded from the analysis.

Selective reporting (reporting bias)

Low risk

No study protocol available. The authors considered only 1 adverse event (muscle fatigue); however, this is 1 of the most important adverse events in clinical practice.

Other bias

Unclear risk

Unable to judge because it is unclear if the groups were similar regarding relevant characteristics at baseline (age, gender, level of pain)

Callaghan 2004

Methods

Randomised controlled trial

Trial protocol registration: not reported

Participants

Country: United Kingdom

Setting: Centre for Rehabilitation Science, Manchester Royal Infirmary, Manchester

Data collection period: not reported

Inclusion criteria: atraumatic peripatellar pain (greater than 6 months and not longer than 3 years), patellofemoral pain was provoked by 1 of the following alone or in combination: prolonged sitting, deep squatting, kneeling, ascending or descending stairs

Exclusion criteria: epilepsy, cancer, cardiac pacemaker, suspected heart problem, recent surgery (not including arthroscopy). In order to exclude abnormal foot and ankle pronation as the cause of patellofemoral pain, the participants were screened by kinetic gait analysis to detect abnormal values of mediolateral force. Presence of other lower extremity dysfunction that could account for the knee symptoms

Mean duration of symptoms: not reported

All unilateral complaints

Study participants: 80 people with patellofemoral pain assigned and 74 assessed

  1. NMES (simultaneously delivered, mixed frequency): n = 38/available for analysis = 37

  2. NMES (fixed frequency): n = 41/available for analysis = 37

Mean age (SD): 35 (11.4) years

Gender (number of women/men): 43/31

Interventions

Comparison: NMES (simultaneous mixed frequencies) versus control NMES (fixed frequency)

Treatment duration: 6 weeks
Treatment setting: at home

Details of interventions:

  1. NMES device with simultaneously delivered, mixed frequency: 2‐channel portable, asymmetrical biphasic pulse, maximum amplitude of 90 mA, duty cycle of 10:50 delivering 90 impulses/min, pulse duration 200 μs. Stimulation pattern: simultaneously delivered frequency components of 83, 50, 2.5, and 2 Hz with a doublet of pulses (125 Hz) at the beginning of each pulse train. The pulse train was repeated once every minute and consisted of the following interpulse intervals: 8, 12, 20, 20, 20, 400, and 500 ms. 2 self adhesive electrodes over the quadriceps muscle group, 1 placed on the upper lateral thigh and the other on the lower medial thigh. Treatment duration: 60 minutes daily.

  2. NMES device with fixed frequency: Asymmetric biphasic rectangular waveform, maximum amplitude 100 mA, duty cycle 10:50 delivering 350 impulses/min, pulse duration 300 μs, fixed frequency of 35 Hz. Four self adhesive electrodes were placed over the quadriceps muscle group. Treatment duration: daily stimulation periods lasting 60 minutes.

Stimulation intensity for both groups was the highest comfortably tolerable for all the participants.

Outcomes

Outcomes analysed in the study and used in this review:

  1. Knee pain: VAS

  2. Knee function: Kujala Patellofemoral Score

  3. Adverse events: muscle fatigue rate assessed by bipolar electrode surface EMG (median frequency calculated at 1‐second intervals during a sustained 60‐second contraction at 60% of maximum)

  4. Lower limb muscle function: functional performance tests: step‐up (the number of steps the participant could climb up onto a 25‐centimetre step), step‐down (the number of steps down a 25‐centimetre step), and squat flexion (the amount of knee flexion participants could achieve from a standing position until the onset of their patellar pain, measured by a universal goniometer)

  5. Muscle strength: quadriceps isometric and isokinetic muscle strength measured through an isokinetic dynamometer (angular velocity at 90°/s)

Follow‐up assessments: 6 weeks (at end of treatment)

Notes

Description of condition: patellofemoral pain syndrome
3 participants were excluded due to device failure.

The trial authors provided additional information on NMES parameters via email (9 March 2015).

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Quote: "Randomization was performed by consulting 4 computer‐generated randomization lists, 1 for each of the 4 stratified groups."

Allocation concealment (selection bias)

Unclear risk

Available information did not permit judgement.

Blinding of participants and personnel (performance bias)
All outcomes

Unclear risk

Participants: Available information did not permit judgement.
Personnel: Quote: "To preserve the blinding for the study, both devices were fully explained to and demonstrated on the patients by an independent investigator"

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

Quote: "The lead investigator who examined and measured the patients was not part of the randomisation process, thus ensuring blindness to the stimulator allocation"

Incomplete outcome data (attrition bias)
All outcomes

High risk

Some participants did not complete the study (12% dropout), and their data were excluded from the analysis. Losses not balanced between groups.

Selective reporting (reporting bias)

Low risk

No study protocol available. The authors considered only 1 adverse event (muscle fatigue); however, this is 1 of the most important adverse events in clinical practice.

Other bias

Low risk

The study appears to be free of other sources of bias. Baseline characteristics were balanced between groups.

Glaviano 2016

Methods

Double‐blinded, randomised sham‐controlled trial

Trial protocol registration: not reported

Participants

Country: United States

Setting: laboratory (single NMES session)

Data collection period: not described

Inclusion criteria: age between 15 and 65, atraumatic knee pain (greater than 3 months), pain with more than 2 of the following activities: jumping, kneeling, prolonged sitting, quadriceps contraction, running, squatting, or stair climbing or when pressure was placed on the patella. Participants were required to score less than 85 of 100 on the Anterior Knee Pain Scale.

Exclusion criteria: previous knee surgery, ligamentous instability, meniscal injury, or other sources of anterior knee pain, such as patellar tendinitis, bursitis, or patella subluxation. Contraindications to electrical stimulation: implanted biomedical devices, history of neuropathy, muscular abnormality, hypersensitivity to electrical stimulation, or active infection where the electrodes would be placed.

Mean duration of symptoms: not reported

People who presented bilateral complaints were included, but only the most symptomatic knee was treated.

Study participants: 22 people with patellofemoral pain assigned and assessed

  1. NMES group: n = 11

  2. Sham group: n = 11

Mean age (SD): 26.0 (7.9) years

Gender (number of women/men): 15/7

Interventions

Comparison: NMES versus placebo

Treatment duration: single session (15‐minute treatment)
Treatment setting: laboratory

Details of interventions:

  1. NMES programme: PENS: biphasic asymmetric square‐wave pattern of 50‐hertz pulse frequency, 70‐microsecond phase duration, and 200‐millisecond stimulus train. 2 channels were used to deliver alternating patterns, mimicking the agonist‐antagonist muscle pattern that is seen in healthy people during functional tasks. Channel 1 consisted of 2 self adhesive electrodes positioned over the agonist muscles (gluteus medius and VMO), and channel 2 consisted of 2 electrodes positioned over the antagonist muscles (the middle of the adductor muscle group and the middle of the hamstrings muscle group). The patterned stimulus was a 200‐millisecond contraction to channel 1, a 200‐millisecond contraction to channel 2, and finally a 120‐millisecond contraction to channel 1. Participants were positioned on a treatment table with the hip and knee flexed to approximately 90º for the single 15‐minute treatment, which resulted in a strong motor contraction visible to the researcher.

  2. Sham group: Participants received a single 15‐minute treatment (identical device settings were applied); however, the amplitude was only increased to 1 mA, which is the minimum stimulus allowed for the device display to light up and activate the timer to replicate a true treatment, even though no participant could perceive stimulation. The electrodes were placed at the same muscles as described above. Participants were instructed that they were receiving a "subsensory" treatment.

At the end of the intervention, the PENS electrodes were removed, and the participants were instructed to perform 2 functional movements. Outcome data were collected for both tasks.

  • Single‐leg squat: the participant was instructed to stand on the injured leg and squat so that the knee was flexed to more than 60° and then return to the starting position. The participant was instructed to maintain the non‐standing limb at 90° of knee flexion for the duration of the task. The time to perform the task was standardised: 2 seconds to lower and 2 seconds to return to the starting position.

  • Lateral step‐down: the participant stood on a step that was normalised to 10% of his or her height, lowered himself or herself until the contralateral heel touched a force plate, and then returned to the starting position. A 4‐second time period was also used for this task.

Outcomes

Outcomes analysed in the study and used in this review:

  1. Knee pain: VAS: participants placed a vertical mark on a 10‐centimetre VAS line for the pain they experienced during both tasks.

Follow‐up assessments: immediately at the end of the single‐session treatment (after completing the single‐leg squat and lateral step‐down)

Notes

Description of condition: patellofemoral pain

The trial authors provided additional information on random sequence generation, allocation concealment, and blinding (participants, personnel, and assessors) via email (12 August 2016).

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Available information did not permit judgement.

Allocation concealment (selection bias)

Unclear risk

Quote: "One researcher concealed treatment interventions in envelopes, which were randomly allocated to participants before enrolment."

The authors did not mention if the envelopes were sealed and opaque.

Blinding of participants and personnel (performance bias)
All outcomes

Unclear risk

Quote: "sham controlled laboratory study"

Since the authors did not exclude people who had received previous NMES therapy, it is difficult to affirm that the blinding was effective.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Quote: "At the conclusion of the 15‐minute treatment, electrodes were removed, the blinded researcher left the laboratory, and the primary researcher returned to the laboratory to conduct post‐intervention assessments"

It is not clear if the outcome assessor was blinded.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

All participants completed the study.

Selective reporting (reporting bias)

High risk

No study protocol available. It is unclear if the results included all expected outcomes. This study did not consider adverse event as an outcome. Another report of this study that included a subgroup of 15 females presented the same baseline characteristics (age, height, mass, anterior knee pain score, and VAS pain knee) as those for the 22 participants in the study.

Other bias

Unclear risk

Although the baseline characteristics were balanced between groups, we are uncertain whether these are correct. The pain scores (1.9 in both groups) were below the threshold ("more than 2") for inclusion in the trial.

Gobelet 1992

Methods

Randomised controlled trial

Trial protocol registration: not reported

Participants

Country: Switzerland

Setting: Physical Medicine and Rehabilitation, Sion Hospital, Switzerland and Orthopaedic Hospital of Lausanne

Data collection period: not reported

Inclusion criteria: non‐traumatic retropatellar painful chondropathy, without radiological lesion, with or without Wiberg patellar dysplasia type I or II

Exclusion criteria: Wiberg dysplasia type III

Mean duration of symptoms: not reported

% of bilateral complaints not reported.

Study participants: 120 people with patellofemoral pain assigned and 94 assessed

  1. NMES: n = 28 assessed

  2. Isokinetic exercise: n = 40 assessed

  3. Isometric exercise: n = 26 assessed

Mean age (SD): 26.4 (11.2) years
Gender (number of women/men): 50/44

Interventions

Comparison: NMES versus exercise (isokinetic) versus exercise (isometric)

Treatment duration: 4 weeks
Treatment setting: at home

Details of co‐interventions:

  1. NMES programme: 4‐channel portable device, monophasic or biphasic rectangular waveform, pulse duration 200 μs, duty cycle of 15:45, frequency of 10 and 50 Hz. Stimulation pattern: 60 minutes at 10 Hz continuous, 30 minutes at 50 Hz with tetanic contractions, and 30 minutes at 10 Hz continuous. Electrodes were positioned over the VMO. Treatment duration: 2 hours, twice a day, daily.

  2. Isokinetic exercise: Isokinetic exercises using an isokinetic dynamometer (Cybex II): flexion/extension (angular velocity between 30°/s and 300°/s). Series lasted 1 minute, with a break of 30 seconds to 2 minutes. Treatment duration: 25 to 30 minutes, 3 times a week.

  3. Isometric exercise: Relaxation of the external passive structures, stretching the hamstrings and rectus, and a static proprioceptive rehabilitation. Treatment duration: 30 to 45 minutes, 3 times a week.

Outcomes

Outcomes analysed in the study and used in this review:

  1. Knee function: Arpège function scale

  2. Muscle strength: quadriceps isometric and isokinetic strength using an isokinetic dynamometer (angular velocity at 30°/s and 300°/s)

Follow‐up assessments: 4 weeks (at end of treatment)

Notes

Description of condition: retropatellar chondropathy

It was not possible to obtain additional data on random sequence generation, allocation concealment, and blinding (participants, personnel, and assessors) after attempt to contact authors by email (9 March 2015).

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Available information did not permit judgement.

Allocation concealment (selection bias)

Unclear risk

Available information did not permit judgement.

Blinding of participants and personnel (performance bias)
All outcomes

High risk

Participants: probably not done because the interventions were different between groups.
Personnel: probably not done due to the nature of the intervention.

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

Quote: "The evaluation of the isokinetic strength and Arpège criteria was performed by a neutral observer. This investigator does not belong to the rehabilitation team"

Incomplete outcome data (attrition bias)
All outcomes

High risk

Some participants did not complete the study (22% dropout) and it is unclear how the authors dealt with these missing data. Losses imbalanced between the groups.

Selective reporting (reporting bias)

Unclear risk

No study protocol available. It is unclear if the results included all expected outcomes. This study did not consider adverse event as an outcome.

Other bias

Unclear risk

This study provided no information on the side(s) affected, and it is unclear which knee was treated.

Kaya 2013

Methods

Randomised controlled trial

Trial protocol registration: not reported

Participants

Country: Turkey

Setting: Faculty of Medicine, Department of Sports Medicine, Hacettepe University, Ankara

Data collection period: not reported

Inclusion criteria: pain longer than 6 months, presence of retropatellar pain, crepitation and pain in patellar grinding, age between 18 to 40 years, no abnormalities on magnetic resonance imaging

Exclusion criteria: history or clinical evidence of patellofemoral dislocation, subluxation, or osteoarthritis, presence in the clinical examination of injury or dysfunction to the knee ligaments, bursae, menisci, and synovial plicae, history of lower extremity surgery, radiographic evidence of osteoarthritis in any compartments of the knee joint.

Mean duration of symptoms: not reported

All unilateral complaints

Study participants: 30 participants with patellofemoral pain assigned and assessed

  1. NMES + exercises + patellar taping (n = 15)

  2. Exercises + patellar taping (n = 15)

Mean age (SD): 42.7 (10.0) years

Gender (number of women/men): only women were included.

Interventions

Comparison: NMES + other intervention (exercise + taping) versus no NMES + same other intervention

Treatment duration: 6 weeks

Treatment setting: outpatient rehabilitation programme

Details of interventions:

  1. NMES programme: Portable HVPGS, monophasic (twin‐peak pulse) waveform, pulse duration 65 to 75 µs, intensity amplitude ranges from 0 to 300 V, pulse frequency of 60 pulses per second. The proximal electrode was placed 4 cm superior to the superomedial border of the patella, and the distal electrode was placed 3 cm medial to the first point. Participants in sitting position with their knees extended were ordered to perform quadriceps isometric exercise with the stimulation. The intensity of stimulation was adjusted to produce a strong contraction without causing patellofemoral pain. Treatment duration: 20 minutes, 5 times a week.

  2. Home exercise programme: Isometric quadriceps exercises in sitting, straight leg raise exercises (neutral position) with ankle weights, terminal knee extension exercises with ankle weights, wall squats with ball between the knees, split squats with elastic band (blue colour), step‐down exercises (backward, forward, and sideway), and single‐leg balance exercises in different knee angles with elastic band (blue colour). Stretching exercises included quadriceps, iliotibial band, hamstrings, and gastrocnemius muscles.

  3. Patellar‐taping technique described by McConnell to correct patellar malposition. First a subtape was applied, while taking care not to place any tension on the participant’s skin. After the application of a subtape, a corrective tape was applied. Corrections were applied to obtain anterior tilt, medial glide, medial tilt, and unloading the fat pad until the participant’s pain was reduced by at least 50%.

Outcomes

Outcomes analysed in the study and used in this review:

  1. Knee pain: VAS

  2. Knee function: Lower Extremity Functional Scale (LEFS)

Follow‐up assessments: short term (6 weeks)

Notes

Description of condition: patellofemoral pain syndrome

This trial had 3 treatment arms. Data from 1 group (NMES alone) were not included in this review.

It was not possible to obtain additional data on random sequence generation, allocation concealment, and blinding (participants, personnel, and assessors) after attempt to contact the authors by email (10 March 2015).

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Quote: “The patients were randomly allocated into three groups by the second author who was blinded in measurements and assessments”

The sentence above is unclear about the method used.

Allocation concealment (selection bias)

Unclear risk

Available information did not permit judgement.

Blinding of participants and personnel (performance bias)
All outcomes

High risk

Participants: probably not done because the interventions were different between groups.
Personnel: probably not done due to the nature of the intervention.

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

Quote: “The patients were randomly allocated into three groups by the second author who was blinded in measurements and assessments”

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Quote: "All patients completed the rehabilitation program and all assessment procedures"

Selective reporting (reporting bias)

High risk

No study protocol available. It is unclear if the results included all expected outcomes. This study did not consider adverse event as an outcome. The conclusions for pain were contradicted by the data, raising doubts regarding their reliability.

Other bias

High risk

Baseline characteristics were balanced between groups, except for pain, which was significantly lower in the control group for all 3 functional activities.

Tunay 2003

Methods

Randomised controlled trial

Trial protocol registration: not reported

Participants

Country: Turkey

Setting: Hacettepe University, School of Physiotherapy and Rehabilitation, Sports Physiotherapy and Gulhane Military Medical Academy, Department of Orthopaedics and Traumatology, Ankara

Data collection period: not reported

Inclusion criteria: unilateral patellofemoral pain lasting more than 1 month

Exclusion criteria: history or clinical findings of patellar dislocation, meniscal or ligamentous injury, synovial plicae, knee surgery or trauma

Mean duration of symptoms: 1.8 years (range 1 month to 5 years)

All unilateral complaints

Study participants: 40 people with patellofemoral pain assigned and assessed

  1. NMES + exercises + patellar taping + ice (n = 20)

  2. Exercises + patellar taping + ice (n = 20)

Mean age (SD): 32.9 (7.3) years

Gender (number of women/men): no information

Interventions

Comparison: NMES + other intervention (exercise, taping, and ice) versus no NMES + same other intervention

Treatment duration: 3 weeks (total of 15 sessions)
Treatment setting: outpatient rehabilitation programme

Details of interventions:

  1. NMES programme: Frequency of 30 Hz, duty cycle of 5:10, pulse duration 300 μs, pulse intensity: visible contraction. Electrode position was not reported. Stimulation session duration of 10 minutes.

  2. Exercise programme: Terminal knee extension with elastic band, straight leg raise exercise, hip strengthening exercises with elastic band in standing position, lunge exercise, hamstring and iliotibial band stretching exercises with elastic band (2 times a day).

  3. Patellar taping (not described).

  4. Ice (not described).

Outcomes

Outcomes analysed in the study and used in this review:

  1. Knee pain: VAS

  2. Knee function: Cincinnati Knee Rating System

Follow‐up assessments: short term (3 weeks)

Notes

Description of condition: patellofemoral pain syndrome

This trial had 4 treatment arms. Data from 2 groups (NMES, ice, medial patellar glide and exercises; ice and home exercises) were not included in this review.

The trial authors provided additional information on NMES parameters and exercise programme via email, confirming that "same exercises were given to the all groups" (12 March 2015).

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Available information did not permit judgement.

Allocation concealment (selection bias)

Unclear risk

Available information did not permit judgement.

Blinding of participants and personnel (performance bias)
All outcomes

High risk

Participants: probably not done because the interventions were different between groups.
Personnel: probably not done due to the nature of the intervention.

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Available information did not permit judgement, but seems unlikely given the nature of the intervention.

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is not clear if there were losses.

Selective reporting (reporting bias)

Unclear risk

No study protocol available. It is unclear if the results included all expected outcomes. This study did not consider adverse event as an outcome.

Other bias

Low risk

The study appears to be free of other sources of bias. Baseline characteristics were balanced between groups.

EMG: electromyography
HVPGS: high‐voltage pulsed galvanic simulation
mA: milliamp
NMES: neuromuscular electrical stimulation
PENS: patterned electrical neuromuscular stimulation
SD: standard deviation
VAS: visual analogue scale
VMO: vastus medialis oblique

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Dursun 2001

The purpose of this randomised controlled trial was to investigate the effects of electromyographic biofeedback treatment in people with patellofemoral pain (biofeedback group versus control group). No neuromuscular electrical stimulation intervention.

Kuru 2012

This was not a randomised or quasi‐randomised controlled trial.

Characteristics of ongoing studies [ordered by study ID]

NCT02441712

Trial name or title

Rehabilitation with patterned electrical neuromuscular stimulation for patients with patellofemoral pain (PENS for PFP)

Methods

Randomised controlled trial

Participants

Country: United States

Setting: University of Virginia, Charlottesville

Data collection period: this study was recruiting participants (verified May 2015)

Inclusion criteria: insidious onset of symptoms, presence of peripatellar or retropatellar knee pain during at least 2 of the following functional activities: stair ascent or descent, running, kneeling, squatting, prolonged sitting, jumping; pain for more than 3 months (> 3/10 on VAS); 85 or less on the Anterior Knee Pain Scale

Exclusion criteria: previous knee surgery; internal derangement; ligamentous instability, other sources of anterior knee pain (patella tendonitis, Osgood Schlatter, knee plica, etc.), neurological involvement, any biomedical device; muscular abnormalities; currently pregnant; hypersensitivity to electrical stimulation; active infection over the site of the electrode placement

Study participants: people with patellofemoral pain, ages between 15 and 40 years, both genders

Estimated sample: 32 participants

Interventions

Comparison: NMES versus placebo

Treatment duration: single session (15‐minute treatment)
Treatment setting: outpatient rehabilitation programme

Details of interventions:

  1. PENS: Motor PENS will be a strong triphasic stimulation pattern to the hip, quadriceps, hamstring, and adductors for strength training (50 Hz impulses for 200 ms every 1500 ms). The stimulus will be administered for 15 minutes followed by the impairment rehabilitation programme.

  2. Sham group: Subsensory PENS will be a subsensory stimulus also administered by a triphasic stimulation pattern to the hip, quadriceps, hamstring, and adductors (50 Hz impulses for 200 ms every 1500 ms). The stimulus will be administered for 15 minutes followed by the impairment rehabilitation programme.

Outcomes

Data collection was planned for 4 weeks.

  • Changes in pain assessed by VAS

  • Changes in muscle strength (quadriceps, hamstring, gluteus medius, hip adductor)

  • Changes in participant‐reported outcomes on pain and function before and after the intervention (Anterior Knee Pain Scale, the Activities of Daily Living Scale, the Godin Leisure Scale, and the Fear Avoidance Belief Questionnaire)

Starting date

4 May 2015

Contact information

Neal Glaviano, MEd, ATC

University of Virginia, Charlottesville, Virginia, United States 22902, 434‐924‐6184; email: [email protected]

Notes

A related laboratory study testing the same intervention from the same team is available (Glaviano 2016).

A check on the status of this trial on 1 May 2017 found that "The recruitment status of the study is unknown. The completion data has passed and the status has not been verified in more than two years."

NMES: neuromuscular electrical stimulation
PENS: patterned electrical neuromuscular stimulation
VAS: visual analogue scale

Data and analyses

Open in table viewer
Comparison 1. NMES versus placebo (sham device)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Knee pain during activities (end of the treatment, single 15‐minute NMES session): VAS scale: 0 to 10; higher score = worse pain Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Analysis 1.1

Comparison 1 NMES versus placebo (sham device), Outcome 1 Knee pain during activities (end of the treatment, single 15‐minute NMES session): VAS scale: 0 to 10; higher score = worse pain.

Comparison 1 NMES versus placebo (sham device), Outcome 1 Knee pain during activities (end of the treatment, single 15‐minute NMES session): VAS scale: 0 to 10; higher score = worse pain.

1.1 Pain during a single‐leg squat

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Pain during a lateral step‐down

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Open in table viewer
Comparison 2. NMES (+ other intervention) versus no NMES (+ same other intervention)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Knee pain (end of the treatment, 3 to 12 weeks): VAS scale: 0 to 10; higher score = worse pain Show forest plot

3

118

Mean Difference (IV, Fixed, 95% CI)

‐1.63 [‐2.23, ‐1.02]

Analysis 2.1

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 1 Knee pain (end of the treatment, 3 to 12 weeks): VAS scale: 0 to 10; higher score = worse pain.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 1 Knee pain (end of the treatment, 3 to 12 weeks): VAS scale: 0 to 10; higher score = worse pain.

2 Knee pain during activities (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Analysis 2.2

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 2 Knee pain during activities (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 2 Knee pain during activities (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain.

2.1 Pain during step‐down

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Pain during step‐up

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.3 Pain during squat

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Knee function (end of the treatment, 3 and 6 weeks): Cincinnati Knee Rating System and LEFS; higher score = better function Show forest plot

2

70

Std. Mean Difference (IV, Fixed, 95% CI)

0.37 [‐0.11, 0.84]

Analysis 2.3

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 3 Knee function (end of the treatment, 3 and 6 weeks): Cincinnati Knee Rating System and LEFS; higher score = better function.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 3 Knee function (end of the treatment, 3 and 6 weeks): Cincinnati Knee Rating System and LEFS; higher score = better function.

4 Change score for KPS (end of treatment, 12 weeks) (0 to 100; higher score = better function) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Analysis 2.4

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 4 Change score for KPS (end of treatment, 12 weeks) (0 to 100; higher score = better function).

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 4 Change score for KPS (end of treatment, 12 weeks) (0 to 100; higher score = better function).

5 Good or normal muscle strength (end of the treatment, 6 weeks): grades 4 to 5 Lovett’s manual muscle scale Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

Analysis 2.5

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 5 Good or normal muscle strength (end of the treatment, 6 weeks): grades 4 to 5 Lovett’s manual muscle scale.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 5 Good or normal muscle strength (end of the treatment, 6 weeks): grades 4 to 5 Lovett’s manual muscle scale.

6 Muscle strength (end of the treatment, 12 weeks): isokinetic dynamometer (N) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Analysis 2.6

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 6 Muscle strength (end of the treatment, 12 weeks): isokinetic dynamometer (N).

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 6 Muscle strength (end of the treatment, 12 weeks): isokinetic dynamometer (N).

6.1 Isometric strength with 30° knee flexion

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Isometric strength with 60° knee flexion

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Open in table viewer
Comparison 3. NMES versus exercise

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Knee function (end of the treatment, 4 weeks): Arpège function scale: 0 to 18; higher score = better function Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Analysis 3.1

Comparison 3 NMES versus exercise, Outcome 1 Knee function (end of the treatment, 4 weeks): Arpège function scale: 0 to 18; higher score = better function.

Comparison 3 NMES versus exercise, Outcome 1 Knee function (end of the treatment, 4 weeks): Arpège function scale: 0 to 18; higher score = better function.

2 Muscle strength (end of the treatment, 4 weeks): isokinetic dynamometer (Nm) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Analysis 3.2

Comparison 3 NMES versus exercise, Outcome 2 Muscle strength (end of the treatment, 4 weeks): isokinetic dynamometer (Nm).

Comparison 3 NMES versus exercise, Outcome 2 Muscle strength (end of the treatment, 4 weeks): isokinetic dynamometer (Nm).

2.1 Isokinetic dynamometer at 30°/s

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Isokinetic dynamometer at 300°/s

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Open in table viewer
Comparison 4. NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Knee pain (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Analysis 4.1

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 1 Knee pain (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain.

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 1 Knee pain (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain.

1.1 Simultaneous versus sequential delivery

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Knee function (end of the treatment, 6 weeks): KPS: 0 to 100 scale; higher score = better function Show forest plot

2

88

Mean Difference (IV, Fixed, 95% CI)

‐1.16 [‐6.79, 4.47]

Analysis 4.2

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 2 Knee function (end of the treatment, 6 weeks): KPS: 0 to 100 scale; higher score = better function.

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 2 Knee function (end of the treatment, 6 weeks): KPS: 0 to 100 scale; higher score = better function.

2.1 Simultaneous versus sequential delivery

1

14

Mean Difference (IV, Fixed, 95% CI)

‐5.90 [‐16.14, 4.34]

2.2 Simultaneous versus fixed delivery

1

74

Mean Difference (IV, Fixed, 95% CI)

0.90 [‐5.84, 7.64]

3 Functional performance (end of the treatment, 6 weeks): number of steps up and down until pain Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Analysis 4.3

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 3 Functional performance (end of the treatment, 6 weeks): number of steps up and down until pain.

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 3 Functional performance (end of the treatment, 6 weeks): number of steps up and down until pain.

3.1 Simultaneous versus sequential delivery

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Quadriceps isometric muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm) Show forest plot

2

88

Mean Difference (IV, Fixed, 95% CI)

‐1.15 [‐16.24, 13.94]

Analysis 4.4

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 4 Quadriceps isometric muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm).

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 4 Quadriceps isometric muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm).

4.1 Simultaneous versus sequential delivery

1

14

Mean Difference (IV, Fixed, 95% CI)

3.40 [‐25.83, 32.63]

4.2 Simultaneous versus fixed delivery

1

74

Mean Difference (IV, Fixed, 95% CI)

‐2.80 [‐20.42, 14.82]

5 Quadriceps isokinetic muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm) Show forest plot

2

88

Mean Difference (IV, Fixed, 95% CI)

‐7.28 [‐24.45, 9.89]

Analysis 4.5

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 5 Quadriceps isokinetic muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm).

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 5 Quadriceps isokinetic muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm).

5.1 Simultaneous versus sequential delivery

1

14

Mean Difference (IV, Fixed, 95% CI)

6.10 [‐30.70, 42.90]

5.2 Simultaneous versus fixed delivery

1

74

Mean Difference (IV, Fixed, 95% CI)

‐11.0 [‐30.41, 8.41]

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Comparison 1 NMES versus placebo (sham device), Outcome 1 Knee pain during activities (end of the treatment, single 15‐minute NMES session): VAS scale: 0 to 10; higher score = worse pain.
Figuras y tablas -
Analysis 1.1

Comparison 1 NMES versus placebo (sham device), Outcome 1 Knee pain during activities (end of the treatment, single 15‐minute NMES session): VAS scale: 0 to 10; higher score = worse pain.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 1 Knee pain (end of the treatment, 3 to 12 weeks): VAS scale: 0 to 10; higher score = worse pain.
Figuras y tablas -
Analysis 2.1

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 1 Knee pain (end of the treatment, 3 to 12 weeks): VAS scale: 0 to 10; higher score = worse pain.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 2 Knee pain during activities (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain.
Figuras y tablas -
Analysis 2.2

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 2 Knee pain during activities (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 3 Knee function (end of the treatment, 3 and 6 weeks): Cincinnati Knee Rating System and LEFS; higher score = better function.
Figuras y tablas -
Analysis 2.3

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 3 Knee function (end of the treatment, 3 and 6 weeks): Cincinnati Knee Rating System and LEFS; higher score = better function.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 4 Change score for KPS (end of treatment, 12 weeks) (0 to 100; higher score = better function).
Figuras y tablas -
Analysis 2.4

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 4 Change score for KPS (end of treatment, 12 weeks) (0 to 100; higher score = better function).

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 5 Good or normal muscle strength (end of the treatment, 6 weeks): grades 4 to 5 Lovett’s manual muscle scale.
Figuras y tablas -
Analysis 2.5

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 5 Good or normal muscle strength (end of the treatment, 6 weeks): grades 4 to 5 Lovett’s manual muscle scale.

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 6 Muscle strength (end of the treatment, 12 weeks): isokinetic dynamometer (N).
Figuras y tablas -
Analysis 2.6

Comparison 2 NMES (+ other intervention) versus no NMES (+ same other intervention), Outcome 6 Muscle strength (end of the treatment, 12 weeks): isokinetic dynamometer (N).

Comparison 3 NMES versus exercise, Outcome 1 Knee function (end of the treatment, 4 weeks): Arpège function scale: 0 to 18; higher score = better function.
Figuras y tablas -
Analysis 3.1

Comparison 3 NMES versus exercise, Outcome 1 Knee function (end of the treatment, 4 weeks): Arpège function scale: 0 to 18; higher score = better function.

Comparison 3 NMES versus exercise, Outcome 2 Muscle strength (end of the treatment, 4 weeks): isokinetic dynamometer (Nm).
Figuras y tablas -
Analysis 3.2

Comparison 3 NMES versus exercise, Outcome 2 Muscle strength (end of the treatment, 4 weeks): isokinetic dynamometer (Nm).

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 1 Knee pain (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain.
Figuras y tablas -
Analysis 4.1

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 1 Knee pain (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain.

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 2 Knee function (end of the treatment, 6 weeks): KPS: 0 to 100 scale; higher score = better function.
Figuras y tablas -
Analysis 4.2

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 2 Knee function (end of the treatment, 6 weeks): KPS: 0 to 100 scale; higher score = better function.

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 3 Functional performance (end of the treatment, 6 weeks): number of steps up and down until pain.
Figuras y tablas -
Analysis 4.3

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 3 Functional performance (end of the treatment, 6 weeks): number of steps up and down until pain.

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 4 Quadriceps isometric muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm).
Figuras y tablas -
Analysis 4.4

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 4 Quadriceps isometric muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm).

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 5 Quadriceps isokinetic muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm).
Figuras y tablas -
Analysis 4.5

Comparison 4 NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies), Outcome 5 Quadriceps isokinetic muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm).

Summary of findings for the main comparison. Neuromuscular electrical stimulation + other intervention (e.g. exercise) versus same other intervention only for patellofemoral pain syndrome

Neuromuscular electrical stimulation (NMES) plus other intervention (e.g. exercise) versus no NMES plus same other intervention for patellofemoral pain syndrome

Patient or population: people with patellofemoral pain syndrome1
Settings: outpatient rehabilitation and home‐based therapy
Intervention: NMES2 plus other active intervention (e.g. exercise)3

Comparison: no NMES control plus same other active intervention

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

No NMES plus same other intervention

NMES plus other intervention (e.g. exercise)

Knee pain (short term)
VAS scale: 0 to 10; higher score = worse pain.
Follow‐up: 3 to 12 weeks (all were at the end of the treatment programme2)

The mean knee pain ranged across control groups from
2.36 to 2.70 points.

The mean knee pain in the intervention groups was
1.63 lower
(2.23 to 1.02 lower).

MD ‐1.63 (‐2.23 to ‐1.02)

118
(3 studies)

⊕⊝⊝⊝
very low4

This difference may not be clinically important since the MCID for VAS (1.5 to 2.0, out of 10 points)5 lies within the 95% CI.

Knee pain (long term)
VAS scale: 0 to 10; higher score = worse pain.
Follow‐up: 1 year

The median pain score in the study control group was 0.4 points (IQR 0.2 to 3.4).

The median pain score in the NMES group was 1.8 points (IQR 0.1 to 3.6).

See comment

29
(1 study)

⊕⊝⊝⊝
very low6

The difference was reported as not statistically significant.

Knee function (short term)
2 tools used: Cincinnati Knee Rating System (6 to 100; higher scores = better function) and Lower Extremity Functional Scale (LEFS) scale (0 to 80; higher scores = better function).
Follow‐up: 3 to 6 weeks (at the end of the treatment programme)

The mean knee function in the study control groups was
72.4 (LEFS scale) and 83.3 (Cincinnati score).

The mean difference in knee function in the intervention groups was
0.37 SDs higher
(0.11 lower to 0.84 higher).

SMD 0.37 (‐0.11 to 0.84)

70
(2 studies)

⊕⊝⊝⊝
very low7

0.2 SD represents a small difference, 0.5 SD a moderate difference, and 0.8 SD a large difference.

However, the mean differences in the 2 trials were small and unlikely to be clinically important (LEFS scale: MD 0.73; Cincinnati score: MD 4.65).

Knee function (long term)

Kujala Patellofemoral Score (KPS) (0 to 100; higher score = better function).
Follow‐up: 1 year

The median KPS in the study control group was 95 (IQR 85 to 96).

The median KPS in the NMES group was 94 (IQR 88 to 96).

See comment

29
(1 study)

⊕⊝⊝⊝
very low6

The very small difference was reported as not statistically significant.

Adverse events ‐ not measured

See comment

See comment

Not estimable

See comment

Not measured

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; IQR: interquartile range; MCID: minimal clinically important difference; MD: mean difference; SD: standard deviation; SMD: standardised mean difference; VAS: visual analogue scale

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Where reported, there was a higher percentage of females (63% to 100%). The mean ages of the participants in the four trials ranged from 25 to 39 years. There was a wide duration of symptoms, with the minimum duration of symptoms for trial inclusion ranging from one to six months.
2The format of the NMES varied among the four trials. Sessions of NMES lasted between 10 to 20 minutes, applied 2 to 5 times a week, for between 3 and 12 weeks.
3The co‐intervention in all four trials was exercise. Patellar taping was also applied to all participants in two trials, and ice was applied in one trial.
4We downgraded the evidence two levels due to very serious risk of bias (performance bias), one level for imprecision reflecting small sample size, and one level for indirectness (time point of pain assessment was very far from the end of the intervention).
5The minimal clinically important difference for visual analogue scale usual pain was set at 1.5 to 2.0 (out of 10) points (Crossley et al. Archives of Physical Medicine and Rehabilitation 2004;85(5):815‐22).
6We downgraded the evidence two levels due to very serious risk of bias (performance, detection, and attrition biases) and two levels for imprecision reflecting single‐trial data and small sample size.
7We downgraded the evidence two levels due to very serious risk of bias (performance bias) and one level for imprecision reflecting small sample size.

Figuras y tablas -
Summary of findings for the main comparison. Neuromuscular electrical stimulation + other intervention (e.g. exercise) versus same other intervention only for patellofemoral pain syndrome
Summary of findings 2. Neuromuscular electrical stimulation versus exercise for patellofemoral pain syndrome

Neuromuscular electrical stimulation (NMES) versus exercise for patellofemoral pain syndrome

Patient or population: people with patellofemoral pain syndrome
Settings: at home
Intervention: NMES (2‐hour session, twice a day, every day for 4 weeks)1

Comparison: exercise (either isokinetic or isometric; data combined in the analyses)

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Exercise

NMES

Knee pain (short term: < 3 months)

See comment

See comment

Not estimable

See comment

Not estimable

Knee pain (longer term: > 3 months)

See comment

See comment

Not estimable

See comment

Not estimable

Knee function
(short term)
Arpège function scale (0 to 18; higher score = better function).
Follow‐up: 4 weeks (at end of treatment)

The mean knee function in the study control group was
15.34 points.

The mean knee function in the intervention groups was
0.94 lower
(2.1 lower to 0.22 higher).

MD ‐0.94 (‐2.10 to 0.22)

94
(1 study)

⊕⊝⊝⊝
very low2

Knee function (longer term: > 3 months)

See comment

See comment

Not estimable

See comment

Not estimable

Adverse events

See comment

See comment

Not estimable

See comment

Not measured

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1This very demanding schedule is unlikely to be found in clinical practice.
2We downgraded the evidence two levels for very serious risk of bias (including high risk of performance bias and attrition bias), one level for imprecision (low numbers and wide 95% confidence interval), and one level for indirectness (the scheme used for NMES (during 4 hours/day) does not correspond to that used in clinical practice).

Figuras y tablas -
Summary of findings 2. Neuromuscular electrical stimulation versus exercise for patellofemoral pain syndrome
Comparison 1. NMES versus placebo (sham device)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Knee pain during activities (end of the treatment, single 15‐minute NMES session): VAS scale: 0 to 10; higher score = worse pain Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

1.1 Pain during a single‐leg squat

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 Pain during a lateral step‐down

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 1. NMES versus placebo (sham device)
Comparison 2. NMES (+ other intervention) versus no NMES (+ same other intervention)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Knee pain (end of the treatment, 3 to 12 weeks): VAS scale: 0 to 10; higher score = worse pain Show forest plot

3

118

Mean Difference (IV, Fixed, 95% CI)

‐1.63 [‐2.23, ‐1.02]

2 Knee pain during activities (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2.1 Pain during step‐down

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Pain during step‐up

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.3 Pain during squat

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Knee function (end of the treatment, 3 and 6 weeks): Cincinnati Knee Rating System and LEFS; higher score = better function Show forest plot

2

70

Std. Mean Difference (IV, Fixed, 95% CI)

0.37 [‐0.11, 0.84]

4 Change score for KPS (end of treatment, 12 weeks) (0 to 100; higher score = better function) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5 Good or normal muscle strength (end of the treatment, 6 weeks): grades 4 to 5 Lovett’s manual muscle scale Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

6 Muscle strength (end of the treatment, 12 weeks): isokinetic dynamometer (N) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

6.1 Isometric strength with 30° knee flexion

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Isometric strength with 60° knee flexion

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 2. NMES (+ other intervention) versus no NMES (+ same other intervention)
Comparison 3. NMES versus exercise

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Knee function (end of the treatment, 4 weeks): Arpège function scale: 0 to 18; higher score = better function Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2 Muscle strength (end of the treatment, 4 weeks): isokinetic dynamometer (Nm) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2.1 Isokinetic dynamometer at 30°/s

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Isokinetic dynamometer at 300°/s

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 3. NMES versus exercise
Comparison 4. NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Knee pain (end of the treatment, 6 weeks): VAS scale: 0 to 10; higher score = worse pain Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

1.1 Simultaneous versus sequential delivery

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Knee function (end of the treatment, 6 weeks): KPS: 0 to 100 scale; higher score = better function Show forest plot

2

88

Mean Difference (IV, Fixed, 95% CI)

‐1.16 [‐6.79, 4.47]

2.1 Simultaneous versus sequential delivery

1

14

Mean Difference (IV, Fixed, 95% CI)

‐5.90 [‐16.14, 4.34]

2.2 Simultaneous versus fixed delivery

1

74

Mean Difference (IV, Fixed, 95% CI)

0.90 [‐5.84, 7.64]

3 Functional performance (end of the treatment, 6 weeks): number of steps up and down until pain Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3.1 Simultaneous versus sequential delivery

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Quadriceps isometric muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm) Show forest plot

2

88

Mean Difference (IV, Fixed, 95% CI)

‐1.15 [‐16.24, 13.94]

4.1 Simultaneous versus sequential delivery

1

14

Mean Difference (IV, Fixed, 95% CI)

3.40 [‐25.83, 32.63]

4.2 Simultaneous versus fixed delivery

1

74

Mean Difference (IV, Fixed, 95% CI)

‐2.80 [‐20.42, 14.82]

5 Quadriceps isokinetic muscle strength (end of the treatment, 6 weeks): dynamometer at 90°/s (Nm) Show forest plot

2

88

Mean Difference (IV, Fixed, 95% CI)

‐7.28 [‐24.45, 9.89]

5.1 Simultaneous versus sequential delivery

1

14

Mean Difference (IV, Fixed, 95% CI)

6.10 [‐30.70, 42.90]

5.2 Simultaneous versus fixed delivery

1

74

Mean Difference (IV, Fixed, 95% CI)

‐11.0 [‐30.41, 8.41]

Figuras y tablas -
Comparison 4. NMES (simultaneous frequencies) versus control NMES (sequential or fixed frequencies)